tirzepatide st louis mo STL Medical Weight Loss |

"After the first 20 patients receive treatment, we will pause recruitment to see how well the treatment is working and determine if we can enroll the next 28 patients." To find eligible patients, researchers consider if the person has: Early breast cancer that is ER-positive, which is sensitive to estrogen Early breast cancer that is HER2-negative, which means it doesnt contain proteins that fuel growth Early breast cancer that is lymph node-positive, which means it has spread to nearby lymph nodes A body-mass-index (BMI) of 27 kg/m or above ctDNA-positivity on testing provided by the study No evidence or clinical suspicion of metastatic breast cancer Eligible people who receive tirzepatide treatment in the study aren't required to reach or maintain a specific BMI

PMCID: PMC8608955

Beneficial effects of the melanocortin analogue Nle(4) -d-Phe(7) --MSH in acne vulgaris

Unger, T